





CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016 WEST BENGAL, INDIA Tel : 033-22267333,46019048, Fax : 033-22271324 CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Test Report Status	Final	Results	Biological Reference Interval Units
rest hepoirt status	<u>i illai</u>	Results	Biological Reference Interval Onits

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS, EDTA WHOLE BLOOD HEMOGLOBIN (HB) 14.2 13.0 - 17.0 g/dL METHOD : SPECTROPHOTOMETRY 5.00 RED BLOOD CELL (RBC) COUNT 4.5 - 5.5 mil/µL METHOD : ELECTRICAL IMPEDANCE WHITE BLOOD CELL (WBC) COUNT 7.88 4.0 - 10.0 thou/µL METHOD : ELECTRICAL IMPEDANCE PLATELET COUNT 223 150 - 410 thou/µL METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY **RBC AND PLATELET INDICES** HEMATOCRIT (PCV) 42.1 40 - 50 % METHOD : CALCULATED MEAN CORPUSCULAR VOLUME (MCV) 84.2 83 - 101 fL METHOD : ELECTRICAL IMPEDANCE MEAN CORPUSCULAR HEMOGLOBIN (MCH) 28.3 27.0 - 32.0 pq METHOD : CALCULATED MEAN CORPUSCULAR HEMOGLOBIN 33.6 31.5 - 34.5 q/dL CONCENTRATION (MCHC) METHOD : CALCULATED RED CELL DISTRIBUTION WIDTH (RDW) High 11.6 - 14.0 15.1 % METHOD : ELECTRICAL IMPEDANCE MENTZER INDEX 16.8 MEAN PLATELET VOLUME (MPV) 10.8 fL 6.8 - 10.9 METHOD : CALCULATED WBC DIFFERENTIAL COUNT **NEUTROPHILS** 64 40 - 80 % METHOD : FLOWCYTOMETRY, ELECTRONIC IMPEDANCE & MICROSCOPY. LYMPHOCYTES 27 20 - 40 % METHOD : FLOWCYTOMETRY, ELECTRONIC IMPEDANCE & MICROSCOPY. MONOCYTES 7 2 - 10 % METHOD : FLOWCYTOMETRY, ELECTRONIC IMPEDANCE & MICROSCOPY. EOSINOPHILS 1 - 6 % 2 BASOPHILS 0 0 - 2 % METHOD : FLOWCYTOMETRY, ELECTRONIC IMPEDANCE & MICROSCOPY. ABSOLUTE NEUTROPHIL COUNT 5.04 2.0 - 7.0 thou/µL

METHOD : FLOWCYTOMETRY & CALCULATED











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016 WEST BENGAL, INDIA Tel : 033-22267333,46019048, Fax : 033-22271324 CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ		PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE	: 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RI	ECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		CLIENT PATIENT ID:
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
ABSOLUTE LYMPHOCYTE COUNT	2.13	1 - 3 thou/µL
METHOD : FLOWCYTOMETRY & CALCULATED ABSOLUTE MONOCYTE COUNT	0.55	0.20 - 1.00 thou/µL
METHOD : FLOWCYTOMETRY & CALCULATED	0.55	0.20 - 1.00 thou, με
ABSOLUTE EOSINOPHIL COUNT	0.16	0.02 - 0.50 thou/µL
METHOD : FLOWCYTOMETRY & CALCULATED	0.20	
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10 thou/µL
METHOD : FLOWCYTOMETRY & CALCULATED		
MORPHOLOGY		
RBC	NORMOCYTIC NORMOCHRO	DIMC
METHOD : MICROSCOPIC EXAMINATION		
WBC	NORMAL MORPHOLOGY	
METHOD : MICROSCOPIC EXAMINATION		
PLATELETS	ADEQUATE	
METHOD : MICROSCOPIC EXAMINATION		
ERYTHROCYTE SEDIMENTATION RATE BLOOD	E (ESR), WHOLE	
E.S.R	16 High	0 - 14 mm at 1 hr

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)" GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) METHOD : ENZYMATIC (HEXOKINASE/G-6-PDH)

METHOD : ENZYMATIC (HEXOKINASE/G-6-PDH)			
GLYCOSYLATED HEMOGLOBIN(HBA1C), EI BLOOD	DTA WHOLE		
HBA1C	5.2	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE GLUCOSE(EAG)	102.5	< 116.0	mg/dL


74 - 100

79





mg/dL



SRL LIMITED - KOLKATA REF. LAB Bio-Rad Variant II Turbo CDM 5.4 S/N : 13466

Patient Data
Sample ID:
Patient ID:
Name:
Physician:
Sex:
DOB:

DIAGNOSTIC REPORT

8213576525 0082WB000381 SHAMIMREYAZ

Analysis Data
Analysis Performed:
Injection Number:
Run Number:
Rack ID:
Tube Number:
Report Generated:
Operator ID:

PATIENT REP V2TURBO_A1c


11/02/2023 17:55:07
9026
561
9600
5
11/02/2023 18:39:53

Comments:

Peak Name	NGSP %	Area %	Retention Time (min)	Peak Area
A1a		0.9	0.157	10683
A1b		1.3	0.216	15244
LA1c		1.2	0.391	13660
A1c	5.2		0.491	50368
P3		3.3	0.770	39013
P4		1.5	0.856	17604
Ao		87.5	1.005	1029847

Total Area: 1,176,419

HbA1c (NGSP) = 5.2 %



GLUCOSE, POST-PRANDIAL, PLASMA











ſ

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016 WEST BENGAL, INDIA Tel : 033-22267333,46019048, Fax : 033-22271324 CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Inter	val Units
PPBS(POST PRANDIAL BLOOD SUGAR)	81		140 Normal 140 - 199 Pre-diabetic > or = 200 Diabetic	mg/dL
METHOD : ENZYMATIC (HEXOKINASE/G-6-PDH)				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	170		< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : ENZYMATIC ASSAY				
TRIGLYCERIDES	114		< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : GLYCEROL PHOSPHATE OXIDASE			,,,,	
HDL CHOLESTEROL	36	Low	Low : < 40 High : > / = 60	mg/dL
METHOD : ACCELERATOR SELECTIVE DETERGENT METHOD	OLOGY			
CHOLESTEROL LDL	111			mg/dL
NON HDL CHOLESTEROL	134	High	Desirable: Less than 130 Above Desirable: 130-159 Borderline High: 160-189 High: 190 -219 Very High: >or = 220	mg/dL
METHOD : CALCULATED				
VERY LOW DENSITY LIPOPROTEIN	22.8			mg/dL
CHOL/HDL RATIO	4.7			
LDL/HDL RATIO	3.1			









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,
KOLKATA, 700016
WEST BENGAL, INDIA
Tel : 033-22267333,46019048, Fax : 033-22271324
CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	2	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038	AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEM	I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	ia	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end		
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.		
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid		
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure			
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	< OR = 60)		









CLIENT'S NAME AND ADDRESS :

DIAGNOSTIC REPORT

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD.
KOLKATA, 700016
WEST BENGAL, INDIA
Tel : 033-22267333,46019048, Fax : 033-22271324
CIN - U74899PB1995PLC045956
,,

PATIENT NAME : SHAMIM REYAZ		PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038	AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEM	I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
•			-	

Extreme Risk Group Category B	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or 60<="" =="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

,,			
BILIRUBIN, TOTAL	0.88	0.2 - 1.2	mg/dL
METHOD : DIAZONIUM SALT			
BILIRUBIN, DIRECT	0.33	0.0 - 0.5	mg/dL
METHOD : DIAZO REACTION			
BILIRUBIN, INDIRECT	0.55	0.1 - 1.0	mg/dL
METHOD : CALCULATED			
TOTAL PROTEIN	7.6	6.0 - 8.30	g/dL
METHOD : BIURET			
ALBUMIN	4.4	3.5 - 5.2	g/dL
METHOD : COLORIMETRIC (BROMCRESOL GREEN)			
GLOBULIN	3.2	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.4	1 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	21	5 - 34	U/L
METHOD : ENZYMATIC (NADH (WITHOUT P-5'-P)			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	32	0 - 55	U/L
METHOD : ENZYMATIC (NADH (WITHOUT P-5'-P)			
ALKALINE PHOSPHATASE	55	40 - 150	U/L
METHOD : PARA-NITROPHENYL PHOSPHATE			
GAMMA GLUTAMYL TRANSFERASE (GGT)	24	11 - 59	U/L
METHOD : L-GAMMA-GLUTAMYL-4-NITROANALIDE /GLYCYLGLY	CINE KINETIC METHOD		
LACTATE DEHYDROGENASE	168	125 - 220	U/L
METHOD : IFCC LACTATE TO PYRUVATE			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	11	8.9 - 20.6	mg/dL
METHOD : UREASE METHOD			
CREATININE, SERUM			
CREATININE	0.97	0.60 - 1.30	mg/dL











Units

CLIENT CODE : C000138384

Test Report Status

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

<u>Final</u>

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016 WEST BENGAL, INDIA Tel : 033-22267333,46019048, Fax : 033-22271324 CIN - U74899PB1995PLC045956

Biological Reference Interval

PATIENT NAME : SHAMIM REYAZ	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Results

METHOD : KINETIC ALKALINE PICRATE			
BUN/CREAT RATIO			
BUN/CREAT RATIO	11.34	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	6.9	3.5 - 7.2	mg/dL
METHOD : URICASE			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.6	6.0 - 8.3	g/dL
METHOD : BIURET			
ALBUMIN, SERUM			
ALBUMIN	4.4	3.5 - 5.2	g/dL
METHOD : COLORIMETRIC (BROMCRESOL GREEN)			
GLOBULIN			
GLOBULIN	3.2	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	139	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY INDIRECT			
POTASSIUM, SERUM	4.20	3.5 - 5.1	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY INDIRECT			
CHLORIDE, SERUM	105	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY INDIRECT			











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016
WEST BENGAL, INDIA
Tel: 033-22267333,46019048, Fax: 033-22271324
CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre nocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW	
APPEARANCE	CLEAR	
CHEMICAL EXAMINATION, URINE		
PH	6.0	4.7 - 7.5
SPECIFIC GRAVITY	1.005	1.003 - 1.035
METHOD : DIPSTICK		
PROTEIN	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		
GLUCOSE	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		
BLOOD	DETECTED (+)	NOT DETECTED
METHOD : DIPSTICK		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd 30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD, KOLKATA, 700016 WEST BENGAL, INDIA Tel : 033-22267333,46019048, Fax : 033-22271324 CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ		PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Ye	ars SEX : Male ABHA NO	:
DRAWN : 11/02/2023 10:00 RECEIVED :	11/02/2023 15:17 REPORTED	D: 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTHCARE	LTD (MEDIWHEEL) C	LIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
UROBILINOGEN	NORMAL	NORMAL	
METHOD : DIPSTICK			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : DIPSTICK			
LEUKOCYTE ESTERASE	NEGATIVE	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	1 - 2	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

Comments

URINALYSIS: MICROSCOPIC EXAMINATION IS CARRIED OUT ON CENTRIFUGED URINARY SEDIMENT.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,
KOLKATA, 700016
WEST BENGAL, INDIA
Tel: 033-22267333,46019048, Fax: 033-22271324
CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	2	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038	AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEM	I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:
Test Report Status Final	Results	Biological Reference Interval Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis
HYROID PANEL, SERUM	· · · · · · · · · · · · · · · · · · ·

ТЗ	97.6	35 - 193	ng/dL
METHOD : TWO-STEP CHEMILUMINESCENT MICRO	PARTICLE IMMUNOASSAY		
T4	8.84	4.87 - 11.71	µg/dL
METHOD : TWO-STEP CHEMILUMINESCENT MICRO	PARTICLE IMMUNOASSAY		
TSH (ULTRASENSITIVE)	1.845	0.350 - 4.940	µIU/mL
METHOD : TWO-STEP CHEMILUMINESCENT MICRO	PARTICLE IMMUNOASSAY		







Patient Ref. No. 775000002330199



CLIENT CODE : C000138384

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd	
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROA	۰D,
KOLKATA, 700016	
VEST BENGAL, INDIA	
el : 033-22267333,46019048, Fax : 033-22271324	
CIN - U74899PB1995PLC045956	

Test Report Stat	us Final	Results	Biological Reference I	nterval Units
REFERRING DOCTO	DR : DR. ACROFEMI HE	ALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID	:
DRAWN : 11/02/2	2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/202	23 19:46
ACCESSION NO :	0082WB00038 AG	E: 42 Years SEX : Male	ABHA NO :	
PATIENT NAME	: SHAMIM REYAZ		PATIENT ID:	SHAMM27028082

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PHYSICAL EXAMINATION, STOOL

CONSISTENCY SAMPLE NOT RECEIVED METHOD : MANUAL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP METHOD : GEL CARD METHOD RH TYPE POSITIVE









SRL Ltd

KOLKATA, 700016 WEST BENGAL, INDIA

CIN - U74899PB1995PLC045956

30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,

Tel: 033-22267333,46019048, Fax: 033-22271324



CLIENT CODE : C000138384

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : SHAMIM REYAZ		PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE :	42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECE	IVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTH	ICARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
METHOD : GEL CARD METHOD		
XRAY-CHEST		
IMPRESSION	NO SIGNIFICANT ABNO	ORMALITY DETECTED
TMT OR ECHO		
TMT OR ECHO	ECHO DONE INSTEAD IMPRESSION-NORMAL	
ECG		
ECG	WITHIN NORMAL LIMI	TS
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	NOT SIGNIFICANT	
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT	
RELEVANT FAMILY HISTORY	FATHER : PARKINSON'	S DISEASE, TOBACCO
OCCUPATIONAL HISTORY	NOT SIGNIFICANT	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.72	mts
WEIGHT IN KGS.	78	Kgs
ВМІ	26	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STAT	US HEALTHY	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TE	NDER

NOT ENLARGED

NORMAL

NORMAL



THYROID GLAND

TEMPERATURE

CAROTID PULSATION









ſ

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD
KOLKATA, 700016
WEST BENGAL, INDIA
Tel: 033-22267333,46019048, Fax: 033-22271324
CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ		PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE :	42 Years SEX : Male ABHA N	0:
DRAWN : 11/02/2023 10:00 RECEIV	YED : 11/02/2023 15:17 REPORT	ED: 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEMI HEALTH	CARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
PULSE	79/MINS		
RESPIRATORY RATE	NORMAL		
	111/71		
BP	111/71		mm/Hg
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORMALLY		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			
SPINE	NORMAL		
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	6/6		
	-, -		











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,
KOLKATA, 700016
WEST BENGAL, INDIA
Tel : 033-22267333,46019048, Fax : 033-22271324
CIN - U74899PB1995PLC045956

PATIENT NAME : SHAMIM REYAZ	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038 AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00 RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
DISTANT VISION LEFT EYE WITHOUT GLASSES	6/6	
NEAR VISION RIGHT EYE WITHOUT GLASSES	N6	
NEAR VISION LEFT EYE WITHOUT GLASSES	N6	
COLOUR VISION	NORMAL	
BASIC ENT EXAMINATION		
EXTERNAL EAR CANAL	NORMAL	
TYMPANIC MEMBRANE	NORMAL	
NOSE	NO ABNORMALITY [DETECTED
SINUSES	NORMAL	
THROAT	NO ABNORMALITY [DETECTED
TONSILS	NOT ENLARGED	
BASIC DENTAL EXAMINATION		
TEETH	NORMAL	
GUMS	HEALTHY	
SUMMARY		
REMARKS / RECOMMENDATIONS		OR ANNUAL HEALTH CHECK UP. ON EXAMINATION ONS HE IS FOUND TO BE IN GOOD HEALTH.

Comments

MEDICAL EXAMINATION DONE BY: DR. B. N. JANA, MBBS, DCH CONSULTANT WELLNESS CLINIC PARK STREET, KOLKATA

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when 49.5 years old and NLR = 3.5, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when 49.5 years old and NLR = 3.5, 46.1% covid and 40.1% co

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**



Page 14 Of 17







CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,
KOLKATA, 700016
WEST BENGAL, INDIA
Tel: 033-22267333,46019048, Fax: 033-22271324
CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : DR. ACROFEN	1I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
ACCESSION NO : 0082WB00038	AGE: 42 Years SEX: Male	ABHA NO :
PATIENT NAME : SHAMIM REYA	Z	PATIENT ID : SHAMM27028082

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates) REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin,

ethanol, propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for

well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to : I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured

clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

RL Ltd
0-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,
OLKATA, 700016
/EST BENGAL, INDIA
el : 033-22267333,46019048, Fax : 033-22271324
IN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : DR. ACROFEN	1I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
ACCESSION NO : 0082WB00038	AGE : 42 Years SEX : Male	ABHA NO :
PATIENT NAME : SHAMIM REYA	Z	PATIENT ID : SHAMM27028082

is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget"""'s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson"""'s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and source of normal enzyme activity.Serum GGT has been widely used as an index of liver dysfunction.Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased vestigation of the version o

Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)
Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Mvasthenia Gravis

Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum...Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same

The test is performed by both forward as well as reverse grouping methods.

HISTORY-**** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : SHAMIM REYAZ	2	PATIENT ID : SHAMM27028082
ACCESSION NO : 0082WB00038	AGE : 42 Years SEX : Male	ABHA NO :
DRAWN : 11/02/2023 10:00	RECEIVED : 11/02/2023 15:17	REPORTED : 13/02/2023 19:46
REFERRING DOCTOR : DR. ACROFEM	I HEALTHCARE LTD (MEDIWHEEL)	CLIENT PATIENT ID :
Test Report Status Final	Results	Units

SRL Ltd

KOLKATA, 700016

WEST BENGAL, INDIA

CIN - U74899PB1995PLC045956

Test Report Status <u>Final</u> Results

30-B, CHOWRINGEE MANSION, JAWAHARLAL NEHRU ROAD,

Tel: 033-22267333,46019048, Fax: 033-22271324

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN **ULTRASOUND ABDOMEN** IMPRESSION: No significant abnormality.

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

Dr. B. N. Jana, MBBS, DCH Consultant

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.

2. All tests are performed and reported as per the

turnaround time stated in the SRL Directory of Services.

3. Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

- Test results cannot be used for Medico legal purposes. 8.
- 9. In case of queries please call customer care
- (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



